Advanced Clinical forms scientific and medical affairs division

Chicago, IL (June 9, 2011) - Advanced Clinical, a leading provider of clinical research talent and solutions, has added a Scientific and Medical Affairs Division to its core client offerings. New divisional service offerings include Pharmacovigilance, Regulatory Affairs, Clinical Pharmacology/Translational Medicine, Medical Monitoring, and Quality Assurance. The Division will also encompass Advanced Clinical's already established and proven Medical Writing and Biometric services.

Heading the Scientific and Medical Affairs Division is Dr. Christina Fleming, Advanced Clinical's newly appointed Executive Vice President, Scientific and Medical Affairs. A highly respected leader in medical affairs and clinical services, Dr. Fleming will build, manage, and lead the Division's full range of offerings.

"We are committed to providing our clients with a full range of specialized services and to ensuring that such services are delivered in conjunction with strong clinical insight and expertise," said Dr. Fleming. "Advanced Clinical's new Scientific and Medical Affairs Division will optimize clinical trials and advance discoveries in clinical research, bringing seamless workflow integration to our clients."

About Advanced Clinical: Advanced Clinical provides talent management, a Clinical Research Organization (CRO), technology solutions, and consulting services to the Life Sciences industry. With 15+ years of experience, Advanced Clinical is an established presence in the clinical research field, providing services specifically for Pharmaceutical, Biopharmaceutical, Biotechnology and Medical Device organizations. Advanced utilizes a value-based, "One Team" approach. To learn more, visit http://www.advancedclinical.com.

Suggested Articles

A Roche compound that was designed to treat rheumatoid arthritis could improve the heart's ability to repair itself, a Vanderbilt team found.

After a whirlwind year and two quick-fire raises, cancer startup Black Diamond Therapeutics has nabbed Yumanity, Merck KGaA and SR One veterans to help head up…

In this week's EuroBiotech Report, Lundbeck inks $2 billion Alder buyout, Euro biotechs raise cash and blast rocks Russian smallpox lab.